Navigation Links
NxStage Medical Announces Needle Supply Agreement with DaVita
Date:1/7/2008

LAWRENCE, Mass., Jan. 7 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it has signed a five-year agreement with DaVita, Inc. (NYSE: DVA) to continue to supply DaVita's dialysis centers with MasterGuard and ButtonHole safety needle sets, subject to certain terms and conditions. Safety needles are essential products used to access patients' blood during the vast majority of chronic dialysis therapy treatments. MasterGuard is the leading product in this market, and became part of NxStage's product portfolio through the recent acquisition of Medisystems.

DaVita and its predecessors have a long, successful history with Medisystems brand needles.

"We are very pleased to continue our long-standing relationship as DaVita's primary needle supplier," said Jeffrey H. Burbank, President & CEO of NxStage Medical. "Medisystems' high quality, innovative products was one of the key reasons we acquired the company last year. This new agreement with DaVita solidifies NxStage's position as a dialysis industry leader in-center, as well as in the critical care and home hemodialysis markets."

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, changes relating to customer demand for NxStage's needle and other products and other factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Stephanie Marks of NxStage Medical, Inc.,

1-888-698-6472, ir@nxstage.com

Web site: http://www.nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NxStage Medical to Present at the Piper Jaffray Healthcare Conference on November 27, 2007
2. Arbios Announces SEPET(TM) Manufacturing Agreement With NxStage Medical
3. NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd
4. NxStage Medical Provides Update on Medisystems Acquisition
5. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
6. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
7. Triage study challenges notions of emergency medical response to disaster
8. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
9. Arizona Pain Society and Dr. Robert Barkin, Rush University Medical Center, Present Program on Comprehensive Urine Drug Testing Sponsored by Dominion Diagnostics
10. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
11. Inverness Medical Innovations Acquires ParadigmHealth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... ... June 13, 2017 , ... ... understanding the phenotype of an organism on a molecular level that is ... data processing remain major bottlenecks to biomarker discovery in clinical-based metabolomics research. ...
(Date:6/13/2017)... ... June 13, 2017 , ... ... chosen The Copley Consulting Group to facilitate and deploy Infor’s CloudSuite Industrial ... manufacturing operations and strategic initiatives to increasing customer demands. , “The clients ...
(Date:6/13/2017)... Va. (PRWEB) , ... June 13, 2017 , ... ... Ph.D. will keynote the American Chemical Society (ACS) Green Chemistry Institute’s ... at 8:45 a.m. EST. Dr. Feehery will address other business leaders, policy makers, ...
(Date:6/12/2017)... , ... June 12, 2017 , ... ... safety analytics products and services, today announced that Paul Barrow has joined the ... helping to optimize their signal detection processes and methodologies by leveraging capabilities in ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
Breaking Biology News(10 mins):